Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ORAGENICS INC

Get SEC filing alerts via email and in your feed for ORAGENICS INC

OGEN

ORAGENICS INC

About ORAGENICS INC

Oragenics, Inc. is a development-stage biopharmaceutical company focused on nasal delivery medications for neurology and infectious diseases. Its lead product, ONP-002, aims to treat brain injuries like concussion by rapidly reducing inflammation and swelling via intranasal administration. The company emphasizes proprietary drug formulations, innovative delivery devices, and regulatory pathways to develop and commercialize therapies targeting unmet medical needs in the central nervous system.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ORAGENICS INC

1
1
ORAGENICS INC Oragenics Reports $2.2 Million Net Loss in Q1 2026, No Revenue Generated

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ORAGENICS INC Oragenics Reports $9.8 Million Net Loss for Fiscal Year 2025, Focuses on ONP-002 Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ORAGENICS INC Oragenics Reports $3.07 Million Net Loss in Q3 2025, Focuses on ONP-002 Development

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ORAGENICS INC Oragenics Reports Q2 2025 Financial Results with $2.3 Million Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ORAGENICS INC Oragenics Reports $2.2 Million Net Loss in Q1 2025, Sees Increase in Total Assets

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ORAGENICS INC Oragenics Reports $10.6 Million Net Loss, Plans Phase 2 Trials for ONP-002

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ORAGENICS INC Oragenics Reports Mixed Financial Results, Focuses on ONP-002 Development

Via official filing (AI summary) | over 1 year ago | 0 comments